Medical Affairs, Medtronic Diabetes, Northridge, California, USA.
Research and Development, Medtronic Diabetes, Northridge, California, USA.
Diabetes Technol Ther. 2021 Feb;23(2):104-109. doi: 10.1089/dia.2020.0234. Epub 2020 Aug 14.
The coronavirus disease 2019 (COVID-19) pandemic has challenged the ability to do face-to-face training on advanced diabetes management technologies. In the United States, Medtronic Diabetes shifted from occasional to 100% virtual training on all diabetes devices in mid-March 2020. We studied the outcomes of virtual training on the MiniMed™ 670 G hybrid closed-loop system in type 1 diabetes. From March 20, 2020, to April 22, 2020 (intra-COVID-19), virtual training on the MiniMed 670 G system was completed using Zoom with satisfaction captured through online post-training surveys. Training efficiency was measuring by the days between the date of product shipment and the date of the first and final trainings. Patient satisfaction with training on the MiniMed 670 G was determined by Net Promotor Score (NPS). Uploads from CareLink™ Personal and CareLink Professional and calls to the Medtronic 24-h technical support team requesting educational/software assistance and/or help with health care provider telehealth visits were recorded. Continuous glucose monitoring (CGM) results were measured using the CareLink Personal database. All results except for the Zoom satisfaction survey were compared with data from January 20, 2020, to February 22, 2020, (Pre-COVID-19) when training was performed in-person. The CGM metrics were comparable between pre- and intra-COVID-19 training. The Zoom video conferencing application had 98% satisfaction. The NPS rose from 78 to 84. The time between the pump shipment and the first and last (automode) training was significantly reduced from 14 ± 7 days to 11 ± 5 days ( < 0.001) and from 19 ± 7 days to 15 ± 15 days ( < 0.01), respectively. There was a decrease in the calls for educational assistance to the technical support team but an increase in requests for login and software installation support. Virtual training of individuals with diabetes on the MiniMed 670 G system resulted in high satisfaction and short-term glycemic results comparable with in-person training.
2019 年冠状病毒病（COVID-19）大流行对高级糖尿病管理技术的面对面培训能力提出了挑战。在美国，美敦力糖尿病公司于 2020 年 3 月中旬开始将所有糖尿病设备的培训全部转为 100%虚拟培训。我们研究了 COVID-19 期间，使用虚拟培训对 1 型糖尿病患者的 MiniMed™ 670G 混合闭环系统的效果。从 2020 年 3 月 20 日至 4 月 22 日（COVID-19 期间），使用 Zoom 完成了对 MiniMed 670G 系统的虚拟培训，并通过在线培训后调查收集满意度。培训效率通过产品发货日期与第一次和最后一次培训日期之间的天数来衡量。使用净推荐值（NPS）来确定患者对 MiniMed 670G 培训的满意度。记录 CareLink™ Personal 和 CareLink Professional 的上传情况以及拨打美敦力 24 小时技术支持团队的电话，以寻求教育/软件帮助和/或帮助医疗保健提供者进行远程医疗访问。使用 CareLink Personal 数据库测量连续血糖监测（CGM）结果。除了 Zoom 满意度调查之外的所有结果都与 2020 年 1 月 20 日至 2 月 22 日（COVID-19 之前）进行的培训数据进行了比较。CGM 指标在 COVID-19 之前和期间的培训中是可比的。Zoom 视频会议应用程序的满意度为 98%。NPS 从 78 上升到 84。泵发货后至第一次和最后一次（自动模式）培训之间的时间分别从 14 ± 7 天显著减少到 11 ± 5 天（ < 0.001）和从 19 ± 7 天减少到 15 ± 15 天（ < 0.01）。向技术支持团队请求教育援助的电话减少了，但请求登录和软件安装支持的电话增加了。对 MiniMed 670G 系统的糖尿病患者进行虚拟培训，结果满意度高，短期血糖结果与面对面培训相当。
